Omnicef (cefdinir) is a broad-spectrum, third-generation cephalosporin antibiotic indicated for the treatment of a wide range of bacterial infections in both adults and pediatric patients. It functions by inhibiting bacterial cell wall synthesis, leading to the eradication of susceptible pathogens. This oral suspension and capsule formulation offers a convenient dosing regimen, making it a preferred choice in outpatient settings for compliant, effective therapy against common community-acquired infections.

Features

• Active ingredient: cefdinir
• Available as 300 mg capsules and 125 mg/5 mL oral suspension
• Third-generation cephalosporin antibiotic
• Broad-spectrum activity against Gram-positive and Gram-negative bacteria
• Dosing flexibility for both adult and pediatric populations
• Typically prescribed as a once or twice-daily regimen

Benefits

• Effectively treats common bacterial infections such as pneumonia, bronchitis, sinusitis, and otitis media
• High bioavailability and consistent absorption with or without food
• Lower incidence of Clostridium difficile-associated diarrhea compared to some broader-spectrum antibiotics
• Well-established safety profile in both adult and pediatric patients
• Convenient dosing supports adherence to therapy
• Minimal interference with coagulation parameters, reducing need for monitoring in most patients

Common use

Omnicef is commonly prescribed for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms. These include acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, acute maxillary sinusitis, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections, and acute otitis media. Its spectrum covers common pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes.

Dosage and direction

For most infections in adults and adolescents, the recommended dose is 300 mg every 12 hours or 600 mg once daily for 5–10 days, depending on the infection type and severity. Pediatric dosing is based on weight: 7 mg/kg every 12 hours or 14 mg/kg once daily. The oral suspension should be shaken well before each use. Omnicef may be taken with or without food; however, administration with food may minimize potential gastrointestinal upset. Complete the full course of therapy even if symptoms improve earlier to prevent antibiotic resistance.

Precautions

Patients should be advised to disclose any history of gastrointestinal disease, particularly colitis. Use with caution in patients with renal impairment; dosage adjustment is recommended for creatinine clearance <30 mL/min. May cause false-positive reactions for glucose in the urine with certain tests; use glucose tests based on enzymatic reactions. Prolonged use may result in overgrowth of nonsusceptible organisms.

Contraindications

Omnicef is contraindicated in patients with known hypersensitivity to cefdinir, other cephalosporins, or any component of the formulation. Cross-sensitivity with beta-lactam antibiotics, including penicillins, may occur; caution is advised in patients with penicillin allergy.

Possible side effect

Common adverse reactions include diarrhea (up to 8%), nausea (3%), vaginal moniliasis (3%), headache (2%), and abdominal pain (1%). Less frequently, rash, elevated liver enzymes, and vaginitis may occur. As with other antibiotics, pseudomembranous colitis has been reported. Serious but rare side effects include anaphylaxis, Stevens-Johnson syndrome, and blood dyscrasias.

Drug interaction

Antacids containing magnesium or aluminum and iron supplements may reduce absorption of cefdinir; administer at least 2 hours apart. Probenecid may inhibit renal excretion of cefdinir, increasing serum levels. No clinically significant interaction with warfarin has been noted, but monitoring is advised during concomitant therapy.

Missed dose

If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose to catch up. Resume the regular dosing schedule.

Overdose

Symptoms of overdose may include nausea, vomiting, epigastric distress, and diarrhea. Gastric lavage may be considered. Cefdinir is removed by hemodialysis; supportive measures should be employed based on symptoms.

Storage

Store capsules at controlled room temperature (20–25°C). The reconstituted oral suspension is stable for 10 days at room temperature or under refrigeration; do not freeze. Keep tightly closed and discard any unused portion after the stability period.

Disclaimer

This information is intended for medical education and does not replace professional medical advice. Always consult a healthcare provider for diagnosis and individualized treatment recommendations. Use only as directed by a prescribing physician.

Reviews

Clinical studies and post-marketing surveillance indicate high efficacy and tolerability of Omnicef, particularly in pediatric populations. Healthcare providers frequently note its convenient dosing and broad spectrum as advantageous in outpatient management. Patient-reported outcomes often highlight symptom improvement within 48–72 hours of initiation, with gastrointestinal side effects generally being mild and self-limiting.